Cookies

Like most websites The Analytical Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

HPLC Analysis of Drug-to-Antibody Ratio (DAR) Using BioPro HIC BF

Introduction

Antibody-Drug Conjugates (ADCs) are a recent development of an important class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of people with cancer. ADCs are monoclonal antibodies chemically linked to biologically active small molecule drugs. By combining powerful cell-killing abilities of potent agents with target- specific antibodies, ADCs deliver cytotoxic drugs to the diseased cells, while limiting the toxicity in the non-targeted ones. A significant attribute of ADCs is the average number of drugs conjugated to the antibodies, the drug-to-antibody ratio (DAR). The DAR value affects the efficiency of the drug, as low drug loading reduces the potency, while high drug loading can negatively affect pharmacokinetics and toxicity.

Enjoy our FREE content!

Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE and always will be!

Login if you already created an account

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Analytical Scientist magazine
Register

Or Login as a Guest or via Social Media

Newsletter

Send me the latest from The Analytical Scientist.

Sign up now

Most Popular

Register to The Analytical Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Analytical Scientist magazine

Register